A post-market clinical follow-up (PMCF) study does not end when the last patient enrolls. It runs for years, feeds your Clinical Evaluation Report on a rolling basis, and depends on a small clinical affairs team keeping data quality consistent across dozens of sites with minimal support. Viedoc's EDC software is built for exactly that kind of long-running, lean-team study, with study builds completed in as few as 8 weeks and a no-code Designer your team can run without a vendor programmer. This comparison reviews five EDC platforms for PMCF studies against study design flexibility, long-term patient follow-up capability, EU MDR and FDA compliance coverage, and self-service build speed.
You are not running a Phase III drug trial. You are tracking device performance, adverse events, and patient-reported outcomes over years, often through a mix of registry follow-up, surveys, and chart review, with a clinical affairs team that cannot afford to wait on a vendor programmer every time a follow-up form needs a tweak.
Enterprise EDC platforms built for large pharmaceutical Phase III programs carry dosing-centric terminology, programmer-led build cycles, and pricing structured around per-user fees, none of which fit a PMCF study's long tail and lean staffing. A platform built for device workflows, not retrofitted from pharma, needs to combine fast self-service builds, native long-term follow-up support, and audit-ready compliance from day one.
Best EDC solutions for MedTech PMCF studies, quick comparison
| Platform | Product / module | Overview |
|---|---|---|
| Viedoc | EDC software | Purpose-built EDC and ePRO for medical device studies, with 7,500-plus global studies, a 100% FDA inspection pass rate, and self-service study builds in as few as 8 weeks. |
| Medidata | Rave Lite | A simplified, pre-configured version of Rave EDC aimed at Phase I, Phase IV, and medical device post-market studies, with faster implementation than full Rave EDC. |
| Veeva | Vault EDC | Cloud-native EDC within the Vault Clinical Suite, with a drag-and-drop interface and mid-study amendments without downtime or data migration. |
| Castor EDC | PMCF study software | A no-code EDC platform with PMCF-specific study design templates, automated multi-year patient survey scheduling, and PSUR export tools. |
| Medrio | Medrio CDMS/EDC | A no-code EDC and clinical data management system with offline data capture, aimed at Phase I clinics and MedTech device trials. |
These five eClinical platforms represent the most evaluated options for PMCF studies, reviewed across study design flexibility, long-term follow-up capability, compliance coverage, and self-service build speed.
1. Viedoc
Viedoc's EDC software is purpose-built for device workflows rather than adapted from pharma, with configurable fields for serial numbers, lots, malfunctions, and procedural visits instead of dosing-centric terminology. Across 7,500-plus completed global studies, Viedoc maintains a 100% FDA inspection pass rate, and professional-services builds average 10 weeks, with self-service go-live possible in as little as one day.
For the long follow-up PMCF studies demand, Viedoc's ePRO software captures patient-reported outcomes on automated, multi-year schedules, feeding data straight into the EDC with no manual reconciliation. The no-code Designer means your clinical affairs team can amend follow-up forms in-house as your protocol evolves, without waiting on a vendor programmer.
Viedoc is ISO 27001 and SOC 2 Type II certified, compliant with FDA 21 CFR Part 11, ICH GCP, GDPR, EU Annex 11, and HIPAA, and hosted on Microsoft Azure. The Viedoc Inspection Readiness Packet (VIRP) gives your QA team structured, audit-ready documentation at no additional cost.
"I am most impressed by the usability of the ePRO system and the extremely high compliance that we have been able to reach using the platform," says Amanda M., Sr. Clinical Program Manager, in a verified G2 review.
- Study scale: 8,000-plus global studies with a 100% FDA inspection pass rate
- Build speed: Self-service go-live in as little as one day; professional-services builds average 10 weeks
- Compliance: FDA 21 CFR Part 11, ICH GCP, GDPR, EU Annex 11, HIPAA; ISO 27001 and SOC 2 Type II certified
- Inspection readiness: Viedoc Inspection Readiness Packet (VIRP) included for every customer
- Pricing: Unlimited user seats; transparent, study-based licensing with no per-user fees
- No-code designer: In-house study and follow-up form configuration with no vendor programmer required
2. Medidata
Medidata offers Rave Lite, a simplified, cost-effective version of Rave EDC purpose-built for Phase I, Phase IV, and medical device feasibility and post-market studies. It uses a pre-configured, pre-validated approach designed for faster implementation than full Rave EDC, targeting teams that need to move fast without the overhead of a complete enterprise deployment. Rave Lite supports long-running Phase IV and post-market studies with flexible scaling and simplified operations as requirements evolve over the study's life.
Rave Lite sits alongside Medidata's full Rave EDC platform, which remains the broader Medidata Platform's cornerstone and is oriented toward large-scale, complex pharmaceutical programs. For MedTech teams specifically, Medidata positions Rave Lite as the right-sized entry point, with a flexible pricing model distinct from full Rave EDC's enterprise structure.
3. Veeva
Veeva offers Vault EDC, a cloud-native electronic data capture application within the Veeva Vault Clinical Suite, used across therapeutic areas including medical devices. The platform provides a drag-and-drop, point-and-click build process with no custom programming functions, and supports mid-study amendments to active studies without data migration or downtime.
Vault EDC shares a common data architecture with Vault CTMS, Vault eTMF, and Vault Study Startup, letting data and documents move between clinical operations and data management applications without manual reconciliation. Veeva reports a median study build time across its customer base of roughly 7.4 weeks, with some customers completing builds in four weeks or less. The platform is positioned for sponsors already invested in the wider Vault ecosystem who want unified clinical operations and data management on a single cloud architecture.
4. Castor EDC
Castor EDC offers a dedicated PMCF study software track built specifically for EU MDR post-market clinical follow-up and pre-market clinical investigations. The platform includes PMCF-specific study design templates, automated patient survey scheduling at one, three, and five-year follow-up intervals, and PSUR export tools that generate structured data for Clinical Evaluation Report and periodic safety update report workflows.
Castor's no-code form builder supports registry, survey, and chart-review study types without coding, and its forms meet 21 CFR Part 11 validation standards from the outset. The platform can also pull existing patient data from hospital EHR systems via API to reduce manual entry, and Castor's in-house team offers hands-on study configuration and ongoing data management support for PMCF studies running on the platform.
5. Medrio
Medrio is a no-code EDC and clinical data management system (CDMS) with a long-standing presence in Phase I clinics and MedTech device trials. It combines electronic data capture with eCOA, eConsent, and RTSM in a single platform, and includes offline data capture, a capability particularly valued for remote or lower-connectivity sites.
Medrio positions itself around configuration without a programmer, letting sponsors and CROs adjust study builds and mid-study changes directly. The platform supports data ingestion from wearables, sensors, and lab systems, and Medrio's expert services team offers support from database build through regulatory-ready outputs for sponsors that want hands-on assistance alongside the self-service platform.
What to look for in EDC solutions for MedTech PMCF studies
Native support for long-term, multi-year follow-up
A PMCF study is not a fixed-duration trial. It runs for years, often with follow-up surveys at set intervals well beyond the original investigation, and your EDC needs to schedule and track that follow-up natively rather than forcing your team to manage it in spreadsheets.
Best-in-class platforms support automated, multi-year follow-up scheduling built into the ePRO or eCOA layer, with real-time compliance dashboards that flag participants at risk of missing an assessment window before the data gap becomes permanent.
Overlooking this means your clinical affairs team ends up manually chasing follow-up compliance year after year, which is exactly the kind of ongoing burden a lean PMCF team cannot absorb.
Device-specific study design, not retrofitted pharma workflows
PMCF studies track device performance, malfunctions, and procedural visits, not drug dosing. A platform built around dosing-centric CRF logic forces your team to work around terminology and workflows that were never designed for device studies.
The best platforms offer configurable fields for device serial numbers, lots, and malfunction reporting alongside procedural visit structures, so your forms match how your clinical affairs and QA teams actually think about the study.
Self-service build and amendment speed
PMCF protocols evolve as your regulatory strategy shifts and as new follow-up requirements emerge from your risk management file. A platform that requires a vendor programmer for every amendment turns a routine protocol update into a scheduling dependency.
No-code configuration lets your data management team make changes directly, in days rather than the weeks a programmer-dependent build cycle typically requires.
Regulatory coverage across EU MDR, FDA, and GCP frameworks
PMCF studies frequently span EU MDR requirements alongside FDA and GCP expectations if your device is marketed in multiple regions. Your EDC needs 21 CFR Part 11, ICH GCP, GDPR, and EU Annex 11 coverage as a baseline, not a differentiator, since your QA and regulatory gatekeepers will disqualify non-compliant platforms outright.
Structured, audit-ready validation documentation, not just a certifications list, is what actually shortens your inspection preparation timeline.
How to choose the right EDC solution for MedTech PMCF studies
Step 1: Map your PMCF study design to platform flexibility
Define whether your PMCF study relies primarily on registry follow-up, structured patient surveys, chart review, or a combination of these. A platform's study design tools need to support the specific mix your protocol requires, not a generic pharma-trial template.
Step 2: Assess your team's build and amendment capacity
Evaluate whether your clinical affairs team has the bandwidth to self-build and self-amend studies, or whether you need a vendor's professional services team involved for configuration and ongoing data management. This decision shapes both your total cost of ownership and your control over amendment turnaround.
Step 3: Scrutinize compliance documentation depth, not just certification lists
Look past a list of compliance acronyms and ask what structured, audit-ready documentation the vendor actually provides for your QA team's inspection preparation. The depth of this documentation determines how much internal validation work your lean team has to do itself.
Step 4: Evaluate real-world data completeness support
Since PMCF studies often run for years, check whether the platform can pull existing patient data from hospital EHR systems to reduce manual entry and improve completeness across a multi-year follow-up window, alongside patient-reported outcome capture.
Step 5: Choose a platform built for lean, multi-year device studies
Once you have mapped study design, team capacity, compliance depth, and data completeness needs, choose the platform that fits a lean team running a study measured in years, not months. Viedoc's EDC software is built specifically for this profile, and you can book a demo to see how a PMCF study build maps to your own protocol.
Frequently asked questions
What is the best EDC platform for MedTech PMCF studies?
Viedoc's EDC software is the best choice for MedTech PMCF studies, combining device-specific study design, native long-term ePRO follow-up, and self-service study builds completed in as little as one day for teams building in-house. Viedoc maintains a 100% FDA inspection pass rate across 8,000-plus global studies and includes the Viedoc Inspection Readiness Packet (VIRP) for audit-ready documentation at no added cost. Castor EDC is a strong alternative, with a dedicated PMCF study design track and PSUR export tooling built specifically for EU MDR post-market follow-up. Medidata Rave Lite is a credible option for teams that want a simplified, pre-configured build within the broader Medidata ecosystem.
What should I look for when choosing an EDC platform for PMCF studies?
Look for native support for automated, multi-year patient follow-up scheduling, device-specific study design rather than retrofitted pharma workflows, self-service build and amendment capability, and regulatory coverage spanning EU MDR, FDA 21 CFR Part 11, and ICH GCP. Structured, audit-ready compliance documentation matters more than a bare list of certifications, since it directly shortens your QA team's inspection preparation work.
How long does it take to build and deploy a PMCF study database?
It depends on your approach. Viedoc's self-service customers can bring a database live in as little as one day, while most studies managed through professional services take 8 to 12 weeks from signed work order to go-live, averaging around 10 weeks. Platforms built for programmer-led configuration typically run longer, since every build and amendment routes through a vendor's technical team rather than your own clinical affairs staff.
Which EDC platforms support EU MDR compliance for PMCF studies?
Viedoc supports EU MDR-relevant PMCF workflows through FDA 21 CFR Part 11, ICH GCP, GDPR, and EU Annex 11 compliance, alongside ISO 27001 and SOC 2 Type II certification. Castor EDC also positions specifically for EU MDR PMCF and pre-market clinical investigations, with forms built to 21 CFR Part 11 validation standards from the outset.
Can ePRO software genuinely improve data quality in a multi-year PMCF study?
Yes. Automated, scheduled patient surveys reduce recall bias and eliminate manual transcription errors compared with paper-based or ad hoc follow-up. In a post-market ePRO study Viedoc supported for a medical device company, automated reminders drove 98% visit compliance across more than 1,300 participants, with most completing their visit after a single reminder, showing that engagement infrastructure, not just data capture, is what keeps multi-year follow-up compliant.
Do I need a full eClinical suite for a PMCF study, or is EDC plus ePRO enough?
Most PMCF studies are well served by EDC paired with ePRO for patient-reported follow-up, without needing a full suite of CTMS, eTMF, and RTSM modules built for complex interventional drug trials. Adding modules like eTMF or medical coding makes sense only if your study genuinely needs document management or standardized adverse event coding at scale, not by default.
Making the right EDC choice for MedTech PMCF studies
The EDC platforms reviewed here span a real range of approaches, from enterprise suites built primarily for large pharmaceutical programs and adapted for post-market use, to platforms purpose-built for device-specific, long-running follow-up studies. The global eClinical software market is estimated at over 11 billion dollars in 2025, growing at approximately 14 percent annually, and device-specific post-market study demand is a meaningful part of that growth as EU MDR enforcement matures.
Match your platform choice to your organization's profile: a lean clinical affairs team running a single PMCF study values self-service build speed and device-specific design over suite breadth, while a MedTech company managing several concurrent post-market studies across regions weighs compliance depth and vendor stability more heavily, particularly if EU and US regulatory expectations both apply. Sponsors already committed to Viedoc's broader EDC software for pre-market studies often find continuity into PMCF a natural extension rather than a fresh vendor evaluation, and MedTech teams weighing this decision across their wider device portfolio may find it useful to consult broader guidance on EDC for medical devices.
A PMCF study's switching costs compound over its multi-year life. Choosing a platform that fits your team's actual build capacity and follow-up requirements at the outset avoids a costly mid-study migration later.
Why Viedoc is the best EDC choice for MedTech PMCF studies
Viedoc's EDC software is built for the specific shape of a PMCF study: device-centric workflows, multi-year patient follow-up, and a lean clinical affairs team that needs to move without a vendor programmer standing between them and every protocol update. Across 8,000-plus completed global studies, Viedoc has maintained a 100% FDA inspection pass rate, and self-service customers can bring a study database live in as little as one day.
Operationally, Viedoc pairs the no-code Designer with unlimited user seats and transparent, study-based licensing, so a growing PMCF program does not carry per-user penalties as more staff or sites come online. Viedoc's ePRO software handles the automated, multi-year follow-up surveys a PMCF protocol demands, feeding straight into the same database with no manual reconciliation.
On compliance, Viedoc is ISO 27001 and SOC 2 Type II certified, compliant with FDA 21 CFR Part 11, ICH GCP, GDPR, and EU Annex 11, and includes the Viedoc Inspection Readiness Packet (VIRP) as part of every license, with 24/7 customer success support available across global offices.
If your team is scoping a PMCF study and wants to see how the build maps to your specific device and follow-up schedule, book a demo or request a proposal and we will walk through study design, compliance documentation, and build timeline together.
